Complete metabolic response after carboplatin desensitization in Peritoneal Carcinomatosis.

Rosalaura V Villarreal González Sandra Nora González-DíazOscar Vidal-GutiérrezOmar A Zayas-VillanuevaHugo Solís-LaraWendy J Santos-FernándezClaudio A Casas-MurilloAlfonso López-Méndez

Published in: Journal of oncology pharmacy practice : official publication of the International Society of Oncology Pharmacy Practitioners (2022)

Prolonged carboplatin use is associated with an increased incidence of carboplatin-related hypersensitivity reactions. And in patients that present hypersensitivity reactions, a safe and effective carboplatin desensitization protocol can be carried out to reach the administration of a full dose. Desensitization protocol induces tolerance to a drug temporarily and is dependent on continuous exposure.

Keyphrases

phase ii study
end stage renal disease
drug induced
randomized controlled trial
phase iii
ejection fraction
chronic kidney disease
newly diagnosed
prognostic factors
open label
clinical trial
emergency department
locally advanced
study protocol